Belimumab for Treatment of cGVHD Following Allo-HCT
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Given the role of B cells in the pathophysiology of chronic graft versus host disease (GvHD),
the association between elevated BAFF levels post-transplant in abnormal B-cell homeostasis
and chronic GvHD, and the efficacy of belimumab in the inhibition of soluble human B
lymphocyte stimulator protein (BAFF) signaling, these proof-of-principle findings support the
rational for use of belimumab as treatment of chronic GvHD.The investigators propose a pilot
and feasibility study to assess the safety and tolerability, as well as preliminary efficacy,
of belimumab a treatment of cGvHD following allogeneic hematopoietic cell transplantation
(alloHCT). The investigators' central hypothesis is that belimumab will be well tolerated and
have a favorable effect on chronic GvHD,and we explored therapeutic dosage of belimumab.